Current status of intracavitary chemotherapy.
While the most effective treatment regimens and both short-term and long-term toxicities remain to be determined, it is not unreasonable for clinicians treating patients with minimal residual disease following cisplatin-based systemic chemotherapy for ovarian carcinoma to try cisplatin by the intraperitoneal route.
Markman
M
M
Department of Medicine, Memorial Sloan-Kettering Cancer Center.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002408:Catheters, Indwelling; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D006801:Humans; D007263:Infusions, Parenteral / Q000379:methods*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D010997:Pleural Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents